Chong Kun Dang and GC Biopharma to co-market neutropenia drug Neulapeg

Chong Kun Dang Pharmaceutical has partnered with GC Biopharma to jointly sell neutropenia treatment Neulapeg (pegteograstim).

Under the agreement, Chong Kun Dang will secure exclusive distribution rights for Neulapeg and will jointly conduct domestic sales and marketing with GC Biopharma,

Chong Kun Dang said on Thursday that Neulapeg is a second-generation neutropenia treatment drug developed by GC Biopharma in 2015 using self-developed technology to prevent immune decline and the risk of infection due to decreased neutrophil levels during chemotherapy.

The product is characterized by GC Biopharma's proprietary PEGylation technology, which extends the drug's half-life and enhances its stability compared to existing treatments. Whereas first-generation therapies require four to six doses per cycle, Neulapeg provides the same effect with only one dose per cycle, significantly improving patient convenience.

PEGylation is a technology designed to bind polyethylene glycol (PEG) at specific locations, increasing the purity of the drug and prolonging its effectiveness in the body.

“Neulapeg is an innovative drug that improves patient convenience by dramatically extending the drug administration cycle with GC Biopharma’s proprietary technology,” Chong Kun Dang Pharmaceutical President Kim Young-joo said. “Based on Chong Kun Dang's expertise and sales power in the anticancer sector, we will expand the supply of Neulapeg in the neutropenia treatment market and create synergies between our companies.”

Namkoong Hyun, head of GC Biopharma’s Domestic Sales Division, said, “Through our collaboration with Chong Kun Dang, we look forward to delivering Neurapeg's superior clinical value to various areas, giving cancer patients a better quality of life and hope for a cure.”